Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Efficacy, Cycle Control, and User Acceptability of a Novel Combined Contraceptive Vaginal Ring
The ring is an effective contraceptive with excellent cycle control that is convenient, well tolerated, and highly acceptable to users. Expand
Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiol.
A novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiol 15 microg daily over a period of 3 weeks was tested and offers an effective, convenient, well-accepted and novel method for hormonal contraception. Expand
Efficacy and safety of a contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive: a 1-year randomized trial.
NuvaRing has comparable efficacy and tolerability with a COC containing 150 microg of LNG and 30microg of EE and does not require daily dosing. Expand
Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition.
NuvaRing completely inhibited ovulation throughout the normal 3-week period and the extended period of use, and ovarian suppression after 3 weeks of NuvaRing use was comparable to that on day 21 of DGS/EE COC intake. Expand
Ovarian function with a novel combined contraceptive vaginal ring.
NuvaRing is a highly effective, reversible method of hormonal contraception, at least until the stage of a 13 mm dominant follicle, is prevented and as little as 3 consecutive days of NuvaRing use interferes with follicle growth. Expand
Superior cycle control with a contraceptive vaginal ring compared with an oral contraceptive containing 30 microg ethinylestradiol and 150 microg levonorgestrel: a randomized trial.
BACKGROUND This trial was conducted to compare cycle control with vaginal ring a combined contraceptive vaginal ring, and a combined oral contraceptive (COC) delivering 30 mug ethinylestradiol (EE)… Expand
The pharmacodynamic effects of an oral contraceptive containing 3 mg micronized 17 beta-estradiol and 0.150 mg desogestrel for 21 days, followed by 0.030 mg desogestrel only for 7 days.
The study indicates that the combination of 3.0 mg micronized estradiol and 0.150 mg desogestrel is an effective and safe contraceptive, offering an acceptable cycle control, and the addition of a low dose of desogesting during the pill-free period did not further suppress ovarian activity nor improve the bleeding pattern. Expand
Maintenance of ovulation inhibition with the 75-microg desogestrel-only contraceptive pill (Cerazette) after scheduled 12-h delays in tablet intake.
- T. Korver, C. Klipping, D. Heger-Mahn, I. Duijkers, Gonnie van Osta, T. Dieben
BACKGROUND In contrast to traditional progestagen-only pills (POPs), the desogestrel-only pill Cerazette consistently inhibits ovulation. This study was performed to test the hypothesis that… Expand
The combined contraceptive vaginal ring and bone mineral density in healthy pre-menopausal women.
- R. Massai, L. Mäkäräinen, A. Kuukankorpi, C. Klipping, I. Duijkers, T. Dieben
- Human reproduction
- 1 October 2005
In healthy pre-menopausal women, 2 years of contraceptive ring use produced no changes in BMD, although some degree of acquisition of peak bone mass might have been prevented in the contraceptive ring group. Expand
The combined contraceptive vaginal ring (NuvaRing) and lipid metabolism: a comparative study.
Changes in the lipid profile reflect the lower androgenicity of etonogestrel versus levonorgestrel and show that NuvaRing has a minimal effect on lipid profile. Expand